Mollet Del Valles

Researchers are conducting a 2-year, multicenter observational study to evaluate clinical differences in patients with migraine who are treated with medications targeting calcitonin gene-related peptide (CGRP) or its receptor. These medications include monoclonal antibodies such as erenumab, galcanezumab, fremanezumab, and eptinezumab, as well as gepants like rimegepant and atogepant. The study includes patients diagnosed with migraine according to specific criteria and who meet local reimbursement guidelines for these treatments. Participants will begin treatment with one of the anti-CGRP drugs or gepants, and a baseline assessment will be performed. Follow-up visits will occur every 6 months to monitor treatment effectiveness, side effects, patient-reported outcomes, and eligibility to continue the study medication. The observation period for each participant will last for 2 years. During the study, researchers will track changes in the number of monthly headache days and monthly migraine days as primary outcomes. Participants will undergo regular assessments including clinical evaluations and questionnaires. Safety and treatment adherence will be monitored throughout the two-year observation period to better understand real-world use of these migraine preventive therapies.